1Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus:the 10 year follow-up of the Belfast Diet Study.Diabet Med 1998; 15:290-296.
2Hirsch IB,Bergenstal RM,Parkin CG,Wright E,Buse JB:A real-world approach to insulin therapy in primary care practice.Clin Diabetes 2005,23:78-86.
4Steven E.Kahn,Steven M.Haffner,Mark A.et al.Glycemic Durability of Rosiglitazone,Metformin,or Glyburide Monotherapy.N Eng J Med 2006;355:2427-2443.
5DeFronzo R,Ratner RE,Han J,Kim DD,Fineman MS,Baron AD:Effects of exenatide on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.Diabetes Care 2005; 28:1092-1100.
6Hollander PA,Levy P,Fineman MS,Maggs DG,Shen LZ,Strobel SA,Weyer C,Kolterman OG:Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes.Diabetes Care 2003; 26:784-790.
二级参考文献6
1Weyer. Dificiency in AIR predict IGT and Type 2 diabetes. Diabetes Care, 2001,24 : 89-94.
2Haffner SM, Miettinen H, Gaskill SP, et al. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes, 1995,44: 1386-1391.
3Bruce DG, Chisholm DJ, Leonare H, et al. Physiological importance of deficiency in early prandial insulin secretion in non-in-sulin-dependent diabetes. Diabetes, 1988,37: 736-743.
4Bruttomesso D, Pianta A, Mari A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes, 1999,48: 99-105.
5Ilkova H, glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care, 1997,20:1353-1356.
6Walton C, Godsland IF, Proudler AJ, et al. Effect of body mass index and fat distribution on insulin sensitivity, secretion, and clearance in nonobese healthy men. J Clin Endocrinol Metab,1992,75: 170-175.
6Doupis J, Veves A. DPP4 inhibitors : a new approach in diabetes treatment[J]. Adv Ther, 2008, 25 ( 7 ) : 627-643.
7Tanzi MG. 2015 ADA : CV safety, diabetes self-management and supiort[J]., pharmacy Today, 2015 (10).- 36-37_.
8Merker L, Lund SS, Hantel S, et al. Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes ( T2DM ) with HbAlc > 8%[J]. Diabetologie Und Stoffwechsel, 20!5, 10 ( S 01 ) : $57-$58.
9Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes[J]. N Engl J Med,2016.375(4):311-322.
